Abstract
Summary: Gaucher disease (GD) is a lysosomal storage disorder with a broad, overlapping clinical spectrum. The presented two case reports highlight the clinical evaluation required in neuronopathic GD to assist with medical management and genetic counselling.
REFERENCES
Altarescu G, Hill S, Wiggs E, et al (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 138(4): 539–547.
Goker-Alpan O, Schiffmann R, Park JK, Stubbleffield BK, Tayebi N, Sidransky E (2003) Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 143(2): 273–276.
Jeyakumar M, Norflus F, Tifft CJ, et al (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97(1): 327–329.
Koprivica V, Stone DL, Park JK, et al (2000) Analysis and classiffcation of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66(6): 1777–1786.
Platt FM, Jeyakumar M, Andersson U, et al (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J InheritMetabDis 24(2): 275–290.
Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24(3): 319–327.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hanna, R., McDonald, M.T., Sullivan, J.A. et al. Diagnostic and treatment challenges of neuronopathic Gaucher disease: Two caseswith an intermediate phenotype. J Inherit Metab Dis 27, 687–690 (2004). https://doi.org/10.1023/B:BOLI.0000043027.80328.75
Issue Date:
DOI: https://doi.org/10.1023/B:BOLI.0000043027.80328.75